Clinical trial
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia…
NCT00448019 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00448019 |
|---|---|
| Title | FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) |
| Official title | Fludarabine, Cyclophosphamide, Rituximab and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Fludarabine, Cyclophosphamide, Rituximab, Bevacizumab |
| Enrollment | 64 |
| Start date | Feb 1, 2007 |
| Primary completion | Oct 1, 2014 |
| Completion | Oct 1, 2014 |
| First posted | Mar 15, 2007 |
| Last update posted | Nov 2, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: